Interferon alpha-2 treatment reduces circulating neutrophil extracellular trap (NETs) levels that may play a pathogenic role in the thrombosis in myeloproliferative neoplasms [88]. The gene discussed is IFNA2; the disease is myeloproliferative neoplasm.